Literature DB >> 27575264

Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It.

Allen M Gown1.   

Abstract

CONTEXT: -There are a number of critical factors that can lead to incorrect results if the diagnostic pathologist performing immunohistochemistry is unaware of, or not vigilant about, their influence.
OBJECTIVE: -To highlight 3 arenas in which errors may be introduced. DATA SOURCES: -For choosing the correct primary antibody, selection of the most appropriate antibodies for a given clinical application can be aided by obtaining information from the vendor; however, this can yield incomplete information. There are a number of online databases that have comparisons of antibodies from different vendors, particularly with respect to their use and properties. Reading the published literature can assist in this process, particularly with respect to determining antibody sensitivity and specificity, but it is a daunting task to keep up with all of the immunohistochemistry-related papers published. Finally, Web sites of a number of quality assurance organizations are accessible and can provide a wealth of information comparing the "real world" performance characteristics of different antibodies to the same target protein. False-positive signals can result from a number of factors, including the use of inappropriately high antibody concentration, and "pseudospecific" signal that is in the wrong compartment of the cell. False-negative signal can result from factors such as use of a nonoptimized epitope retrieval method. It is critical that epitope retrieval methods be optimized for each antibody employed in the laboratory.
CONCLUSIONS: -By paying attention to these potential problems, the "black box" of diagnostic immunohistochemistry can be made more transparent.

Mesh:

Substances:

Year:  2016        PMID: 27575264     DOI: 10.5858/arpa.2016-0119-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  19 in total

1.  A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.

Authors:  Steven A Bogen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-02-22

2.  Initial panel of immunocytochemical markers for identification of primary carcinoma site for effusions and peritoneal washings from women.

Authors:  Gustavo Henrique Soares Takano; Rivadávio Fernandes Amorim; Vânia Moraes Ferreira; Leonora Maciel de Souza Vianna; Tercia Maria Mendes Lousa de Castro; Marcos de Vasconcelos Carneiro; Ísis de Araújo Oliveira; Andrea Barretto Motoyama; Fabiana Pirani Carneiro
Journal:  Int J Clin Exp Pathol       Date:  2022-04-15

Review 3.  Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2017-10

4.  A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage.

Authors:  Jeffrey R Whiteaker; Lei Zhao; Rick Saul; Jan A Kaczmarczyk; Regine M Schoenherr; Heather D Moore; Corey Jones-Weinert; Richard G Ivey; Chenwei Lin; Tara Hiltke; Kerryn W Reding; Gordon Whiteley; Pei Wang; Amanda G Paulovich
Journal:  Radiat Res       Date:  2018-02-23       Impact factor: 2.841

5.  A study of HER2 expression in endometrial carcinoma: a single centre experience.

Authors:  Mariani Hashim; Nur Maya Sabrina Tizen; Nurwardah Alfian; Hasmah Hashim; Azmawati Mohammed Nawi; Suria Hayati Md Pauzi
Journal:  Pan Afr Med J       Date:  2021-02-22

6.  Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma.

Authors:  Monika Szymonek; Artur Kowalik; Janusz Kopczyński; Danuta Gąsior-Perczak; Iwona Pałyga; Agnieszka Walczyk; Klaudia Gadawska-Juszczyk; Agnieszka Płusa; Ryszard Mężyk; Magdalena Chrapek; Stanisław Góźdź; Aldona Kowalska
Journal:  Oncotarget       Date:  2017-08-24

7.  Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.

Authors:  Ilka Kristiansen; Carsten Stephan; Klaus Jung; Manfred Dietel; Anja Rieger; Yuri Tolkach; Glen Kristiansen
Journal:  Int J Mol Sci       Date:  2017-05-29       Impact factor: 5.923

8.  PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

Authors:  Vanda F Torous; Deepa Rangachari; Benjamin P Gallant; Meghan Shea; Daniel B Costa; Paul A VanderLaan
Journal:  J Am Soc Cytopathol       Date:  2018-02-16

9.  Epitope Preservation Methods for Tissue Microarrays: Longitudinal Prospective Study.

Authors:  Nicole K Andeen; Regina Bowman; Toni Baullinger; J Mathew Brooks; Maria S Tretiakova
Journal:  Am J Clin Pathol       Date:  2017-11-02       Impact factor: 2.493

10.  Association between Ki-67 Labeling index and Histopathological Grading of Glioma in Indonesian Population.

Authors:  Emilia Theresia; Rusdy Ghazali Malueka; Sofia Pranacipta; Bidari Kameswari; Kusumo Dananjoyo; Ahmad Asmedi; Adiguno Suryo Wicaksono; Rahmat Andi Hartanto; Ery Kus Dwianingsih
Journal:  Asian Pac J Cancer Prev       Date:  2020-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.